CBUS stock forecast, quote, news & analysis
Cibus Inc is a biotechnology company... Show more
Cibus (CBUS) Stock Analysis: Gene-Editing Pipeline Advances Toward a 2027 Latin American Launch
Key Takeaways
- Cibus (CBUS) shares traded near $1.38 recently, down roughly 6% over the trailing 30 days, holding within a relatively narrow range below earlier autumn highs.
- Cibus is an agricultural gene-editing technology company—not a seed company—that develops crop traits using its proprietary Rapid Trait Development System (RTDS) and licenses them to customers for royalties.
- The company is targeting an initial commercial launch of herbicide-tolerant rice in Latin America in 2027, while its U.S. launch timeline has shifted to 2029.
- Second-quarter 2026 results, reported August 13, missed consensus, with revenue near $0.99 million and EPS of -$0.29, weighing on investor sentiment.
- Management is guiding to an annual net cash usage run-rate of roughly $35 million exiting 2026, with cash runway extending into early 2027.
- Regulatory milestones, including the EU's new genomic techniques legislation and Latin American trait confirmations, continue to support the commercialization timeline.
- For additional detail on valuation and expectations, explore Cibus' Price Targets, Earnings, and Forecast pages.
- Investors seeking automated trading insights can explore Trending AI Robots.
Current Market Snapshot
Cibus shares have traded in a comparatively contained range in recent weeks, hovering around $1.38 after pulling back from levels above $1.70 reached in early October. The stock's modest decline over the trailing 30 days reflects a combination of broader small-cap biotechnology volatility, an August earnings miss, and ongoing attention to the company's cash position and commercialization timeline. With a market capitalization around $106 million, Cibus remains a micro-cap development-stage enterprise whose shares are sensitive to pipeline news, regulatory updates, and capital-raising activity rather than to near-term profitability.
Cibus (CBUS) Business Overview and Competitive Position
Cibus, Inc. is a San Diego-based agricultural technology company focused on precision gene editing for major row crops. Its core platform, the Rapid Trait Development System (RTDS), combined with the "Trait Machine" process, enables the company to edit a single cell from a seed company's elite germplasm and grow it into a full plant carrying a desired trait—far faster and less expensively than conventional breeding. Because Cibus is not a seed company, its model centers on licensing edited traits back to seed partners in exchange for royalties.
The company's priority programs include herbicide-tolerance traits (HT1 and HT3) in rice, sustainable ingredients such as biofragrances and crop-based lauric oils, and a broader pipeline spanning canola, nutrient-use efficiency, and emerging soybean and wheat platforms. Cibus has operational crop platforms in rice, canola, winter oilseed rape, flax, and cassava, and has demonstrated single-cell regeneration in eight crops. Investors follow the stock primarily for its path to first commercial royalties, the strength of its partner relationships, and the evolving global regulatory landscape for gene-edited crops.
Recent Developments Driving CBUS
Several developments have shaped sentiment over the past month. On August 13, Cibus reported second-quarter 2026 results that fell short of expectations: revenue of about $0.99 million missed the roughly $1.75 million consensus, and EPS of -$0.29 missed the -$0.19 estimate, contributing to a sharp after-hours decline. Management also raised its projected 2026 net cash usage to approximately $35 million from an earlier target below $30 million, while indicating cash runway extends only into early 2027.
Offsetting these pressures, the company has made tangible commercialization progress. In May, Cibus transferred gene-edited herbicide-tolerance traits into Interoc's elite rice germplasm, a key step toward its anticipated first commercial offering in South America. The company continues to target a 2027 Latin American launch, beginning with Ecuador and Colombia. Leadership changes have also been a focal point: Craig Wichner was appointed CEO effective June 8, 2026, with co-founder Peter Beetham continuing as President and COO.
On the regulatory front, the environment remains supportive. The European Union approved legislation in June 2026 treating certain precision-edited crops on the same basis as conventionally bred varieties, while Ecuador and Peru have confirmed Cibus' HT1 and HT3 rice traits as equivalent to conventional breeding—developments that underpin the Latin American commercialization timeline.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing automated trading systems. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and highest-performing robots appear in this section. These bots vary in trading strategy, holding timeframe, and performance metrics, giving users a way to compare different automated approaches across changing market conditions. The page is designed to help traders identify strategies that align with their own objectives and risk preferences. Exploring the section can offer a practical view of how algorithmic signals are applied to individual stocks and broader market themes.
2026 Outlook and What Investors Should Watch
Looking ahead, the most important near-term catalyst is the company's third-quarter 2026 earnings report, estimated for early November, which will update investors on revenue momentum, cash burn, and progress toward commercialization agreements. Investors should also monitor whether Cibus finalizes definitive commercialization agreements with Latin American rice seed partners, the primary driver of its planned 2027 launch.
Additional watch items include the U.S. rice launch timeline, which hinges on the registration of the partner herbicide (clethodim) and has shifted to 2029; the scale-up of sustainable ingredients orders in the second half of 2026; and the company's ability to manage its cash runway, which currently extends into early 2027. Regulatory decisions in the EU, Latin America, and other markets will continue to influence the pace of commercial adoption. As with any development-stage biotech or agricultural technology company, execution risk, financing risk, and the inherent uncertainty of commercialization timelines remain central considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CBUS turns negative, indicating new downward trend
CBUS saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 77 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CBUS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CBUS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CBUS's RSI Oscillator exited the oversold zone, 35 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBUS advanced for three days, in 210 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
CBUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.093) is normal, around the industry mean (3.498). P/E Ratio (-0.781) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (21.692) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. CBUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology